Skip to content
Screener

Sarepta Therapeutics, Inc. SRPT Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$1.25B-11.7%
BioMarin Pharmaceuticals logo
BioMarin PharmaceuticalsBMRN
$40.22M-77.3%
Insmed logo
InsmedINSM
-$16.62M+94.8%
Capricor Therapeutics logo
Capricor TherapeuticsCAPR
-$34.48M-46.1%
uniQure logo
uniQureQURE
-$79.43M-85.5%
Regenxbio logo
RegenxbioRGNX
$22.7M+132%

Other financials

Income statement

See full
Revenue$401.3M-34.3%
Operating income$13.3M-88.5%
Net income-$4.9M-102%
EPS (diluted)-$0.05-103%

Balance sheet

See full
Cash & equivalents$571.1M+11.9%
Total debt$198.2M-7.6%
Total equity$1.5B+8.8%
Total assets$3.2B-13.4%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$555.0K-98.3%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.77B+1.1%
Enterprise value$1.4B-3.9%
P/S0.9×

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin-6.9%
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-9.3%+2,662pp
Debt / equity0.1×0.0×
Current ratio4.4×+1.5×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:01 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335003
Line itemFor the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Other comprehensive (loss) income:
Unrealized (losses) gains on investments, net of tax(444)(85)(837)167
Total other comprehensive (loss) income(444)(85)(837)167
Comprehensive (loss) income$(5,334)$196,807$325,232$(250,449)
(Loss) earnings per share:
Basic$(0.05)$2.01$3.10$(2.57)
Diluted$(0.05)$1.89$2.99$(2.57)
Weighted average number of shares of common stock used in computing (loss) earnings per share:

Item 1. Financial Statements

FAQ

What is Sarepta Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent?
Sarepta Therapeutics, Inc. (SRPT) reported comprehensive income (loss), net of tax, attributable to parent of -$5.33M in Q2 2026.
How has Sarepta Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Sarepta Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent decreased by 102.7% year-over-year, from $196.81M to -$5.33M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Ask your AI about Sarepta Therapeutics, Inc.'s comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude